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Abstract
Background: Most of breast cancers are considered sporadic and modulation of the two major
genes BRCA1 and BRCA2 expressions caused by tissue-specific somatic mutations lead to this
pathology. The nutritional intake of phytoestrogens seems to reduce the risk of breast cancer and
investigation of their potential as anticancer agents has increased. However, the possible
mechanisms and signalling pathways of phytoestrogen action in breast cancer prevention remains
unknown.
Results: Using Taqman Low Density Array technology, we investigated the BRCA2 loss of function
role in sporadic breast cancers and the links existing with soy isoflavones on a panel of nuclear
receptor expression. Human breast cell lines (MCF-7, MDA-MB-231, and MCF-10a) were
transfected by BRCA2-siRNA and treated with genistein (18.5 μM) or daidzein (78.5 μM) for 72 h.
Generating the transitory knockdown of BRCA2  oncosuppressor, we observed different
modulations in several nuclear receptor genes such as ER, RAR and RXR, as well as PPARs and VDR
according to the studied breast cell line. Additional isoflavone treatments showed different nuclear
receptor gene modulation profiles.
Conclusion: Our results seemed to implicate the oncosuppressor BRCA2 and the phytoestrogen
pathways in different nuclear gene expressions via an ER-independent manner.
Background
Breast cancer is an important public health problem
worldwide. Most of breast cancers are considered spo-
radic, with only an estimated 5–10% due to inherited sus-
ceptibility [1]. Because BRCA1 and BRCA2 expressions are
often decreased, or even absent in sporadic breast cancer,
abnormal BRCA1 or BRCA2 expressions may also play a
role in nonhereditary tumors [2,3]. In sporadic cases,
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BRCA2  gene is rarely inactivated, but its expression is
often modulated [4]. Although BRCA2 function is often
restricted to DNA recombination and repair, evidence is
accumulating that the silencing of this gene might be of
particular importance in the pathogenesis of a significant
proportion of sporadic breast cancers.
Moreover, most of breast cancers are considered estrogen-
dependent, and estrogens are suggested to cause breast
cancer by stimulating cell growth and proliferation
through receptor-mediated processes and via their genoto-
xic metabolites [5,6]. Phytoestrogens are a class of plant-
derived substances that are structurally and/or function-
ally similar to 17β-estradiol (E2) [7]. Interest in phytoes-
trogens, more particularly soy, has been instigated by
epidemiologic studies that have suggested a low incidence
of breast cancer in Asian countries that have high soy
intake [8,9]. It has also been suggested that soy isofla-
vones may influence breast cancer risk via their anti-pro-
liferative, anti-angiogenic, anti-oxidative and anti-
inflammatory properties, but the possible mechanisms of
phytoestrogen actions in breast cancer prevention
remained inconclusive.
Furthermore, nuclear receptors are transcriptional factors
and play key roles in the regulation of gene expression and
physiological activities [10]. To study this, we used RNA
interference in breast human cells to down-regulate
BRCA2 and determine its contribution to nuclear receptor
expression at the transcriptional level. Two different
human breast cancer cell lines (MCF-7, MDA-MB-231)
and a human fibrocystic breast cell line (MCF-10a) were
transfected by a pool of BRCA2-siRNA. They were exposed
to either genistein or daidzein for 72 h. A control group of
non-treated cells was included in our study. Expression
pattern of 64 nuclear receptor genes were investigated
using the TaqMan Low-Density Array (TLDA) technique.
Methods
Cell culture
MCF-7 and MDA-MB-231 breast tumor cell lines came
from a pleural effusion of patients with invasive breast
carcinoma [11,12]. The MCF-10a cell line was established
from breast tissue of patient with fibrocystic breast disease
[13]. All three human cell lines were provided by the
American Type Culture Collection (ATCC). In our study,
MCF-7 were cultured in RPMI 1640 media supplemented
with 2 mM L-glutamine (Invitrogen), 20 μg/ml gentamy-
cin (Panpharma), 10% fetal bovine serum (Invitrogen),
0,04 UI/ml insulin (Novo Nordisk) in a humidified
atmosphere at 37°C containing 5% CO2. This cell line has
a positive estrogen-receptor status (ERα+/ERβ+). MCF-
10a cells were maintained in DMEM-F12 (Invitrogen)
containing 10% horse serum (Invitrogen), 2 mM L-
glutamine, 20 μg/ml gentamycin (Panpharma), 20 ng/ml
epidermal growth factor (Sigma), 100 ng/ml cholera toxin
(Sigma), 0,25 UI/ml insulin (Novo Nordisk) and 0,5 μg/
ml hydrocortisone (Sigma) held at 37°C with 5% CO2.
This cell line has a negative estrogen receptor status (ERα-
/ERβ-). MDA-MB-231 cells were grown in Leibovitch L-15
media with 15% FBS, 20 μg/ml gentamycin (Panpharma),
2 mM L-glutamine in a 37°C humidified atmosphere
without CO2. This cell line has a negative estrogen recep-
tor status (ERα-/ERβ+).
Conditional BRCA2 loss of function using small interfering 
RNA (siRNA)
A pool of three target-specific 20–25 nt BRCA2-siRNAs
was chemically synthesized. The siRNA sequences used
for human BRCA2 were 5'-CCA AGG AUG UUC UGU
CAA Att-3', 5'-CAA GCU ACA UAU UGC AGA Att-3', and
5'-GAA ACG GAC UUG CUA UUU Att-3' (sc-29825, Santa
Cruz Biotechnology). For siRNA treatments, 40–60% sub-
confluent proliferating cells were transfected with 50 nM
of siRNA using the siRNA transfection reagent (sc-29528,
Santa Cruz Biotechnology, California, USA). Prior studies
have established that under these conditions, none of the
siRNA caused cytotoxicity based on cell morphology or
proliferation. To obtain mRNA BRCA2 maximal inhibi-
tion, we carried out 72-h incubations with BRCA2-siRNA
and quantification was performed by real-time quantita-
tive PCR (RT-qPCR).
Phytoestrogen exposure
Isoflavone treatments were carried out for 72 h with 18.5
μM genistein or 78.5 μM daidzein dissolved in dimethyl
sulfoxide (Sigma). These concentrations were previously
obtained and corresponded to the 50% inhibition of the
proliferation (IC50) [14]. As controls, cell lines were also
conditioned in medium without siRNA transfection and
without isoflavone treatments.
RNA extraction and reverse transcription
Total RNA was isolated from MCF-7, MDA-MB-231, and
MCF-10a treated cells and from control cells after 72 h.
We used 1 ml RNA-PLUS (MP Biomedicals) according to
the manufacturer's protocol. The RNA quality was
checked by electrophoresis using a Bioanalyzer 2100 with
RNA 6000 Nano LabChip® and BioSizing A.02.11 soft-
ware (Agilent Technologies). Five micrograms of total
RNA were reverse transcribed in a total volume of 15 μl
using the First-Strand DNA Synthesis Kit and performed
according to the manufacturer's protocol (Amersham Bio-
sciences). Reverse transcriptase was thermically inacti-
vated (95°C, 10 min).
BRCA2 knockdown analyses by quantitative real time RT-
PCR
The resulting cDNA was then quantified with the Taq-
Man® method. PCR was carried out in 96-well plates: 25Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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ng of cDNA and 20 μl of reaction mix containing 12.5 μl
TaqMan universal PCR Master Mix (Roche) (dATP, dCTP,
dGTP and dUTP, MgCl2, AmpliTaqGold, Amperase uracil-
N-glycosylase), 200 nM of TaqMan probes corresponding
to the studied gene, 400 nM of each primer and 50 nM of
18S rRNA primers and TaqMan probe. Primers were as fol-
lows: BRCA2, forward: 5'-CCA AGT GGT CCA CCC CAA
C-3', reverse: 5'-CAC AAT TAG GAG AAG ACA TCA GAA
GC-3'; 18S, forward: 5'-CGG CTA CCA CAT CCA AGG AA-
3', reverse: 5'-GCT GGA ATT ACC GCG GCT-3' (MWG).
Taqman® probes were purchased from Applied Biosys-
tems: BRCA2, 5'-ACT GTA CTT CAG GGC CGT ACA CTG
CTC AAA-3' (FAM); 18S, 5'-TGC TGG CAC CAG ACT TGC
CCT C-3' (VIC).
Data were collected using an ABI PRISM 7700 Sequence
Detector System (Applied Biosystems) for 40 cycles (95°C
for 15 s, 60°C for 1 min) after an initial step of 50°C for
2 min, 95°C for 10 min. The relative amount of BRCA2
mRNA to 18S rRNA was calculated as the average 2-ΔΔCt
where  ΔCT  = CtBRCA2-Ct18S  with data normalized to
untreated controls. Two independent total RNA extrac-
tions were performed as two independent reverse tran-
scriptions with one of the RNA extractions. All data were
generated in triplicate and expressed as mean +/- SD.
TaqMan Low Density Array (TLDA)
Predesigned TLDA called Human Nuclear Receptor Panel
(64 TaqMan® Gene Expression assay preconfigured in a
384-well format, Part n° 4379968 microfluidic cards,
Applied Biosystems), were used in a reverse transcriptase
polymerase chain reaction (RT-PCR) process using the
ABI Prism 7900 HT Sequence Detection System (Applied
Biosystems). The TLDA in this study was configured into
2 identical 64-gene sets in triplicate. A total of 100 μl reac-
tion mixture with 50 μl cDNA template (100 ng) and an
equal volume of TaqMan® universal master mix (Applied
Biosystems) was added to each line of TLDA after gentle
vortex mixing. Thermal cycler conditions were as follows:
2 min at 50°C, 10 min at 94.5°C and 30 s at 97°C, and 1
min at 59.7°C for 40 cycles. The threshold cycle Ct was
automatically given by SDS2.2 software package (Applied
Biosystems). Relative quantities (RQ) were determined
using the equation: RQ = 2-ΔΔCt. All data were generated
two times (different TLDA plates) in triplicate and
expressed as mean +/- SD.
Results
Down-regulated expression of BRCA2 by RT-PCR
We down regulated the expression of BRCA2 by use of
RNA interference, and quantification was performed by
RT-qPCR in MCF 7, MCF-10a and MDA-MB-231 human
breast cell lines under four conditions: 1) control, 2)
siRNA-BRCA2, 3) siRNA-BRCA2  + genistein, and 4)
Specific knockdown of BRCA2 mRNA expression measured by RT-qPCR in MCF-7, MCF-10a and MDA-MB-231 breast cell  lines after BRCA2-siRNA, BRCA2-siRNA + daidzein, and BRCA2-siRNA + genistein 72-h treatments in comparison to controls Figure 1
Specific knockdown of BRCA2 mRNA expression measured by RT-qPCR in MCF-7, MCF-10a and MDA-MB-231 
breast cell lines after BRCA2-siRNA, BRCA2-siRNA + daidzein, and BRCA2-siRNA + genistein 72-h treatments 
in comparison to controls. The ΔΔCt method and normalization by comparison with controls were used. Values are means 
± SD for n = 3 assays. Statistical analysis was carried out by Student t-test (*, P < 0.05; †, P < 0.01).Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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siRNA-BRCA2 + daidzein. As shown in Figure 1, transfec-
tion of the three human breast cell lines treated with a
pool of BRCA2-siRNA for 72 h significantly decreased the
expression of BRCA2 mRNA compared with control cells.
Nuclear receptor gene modulations by TLDA
Sixty-four genes (48 nuclear receptor genes and 16 endog-
enous controls) were successfully amplified two times in
triplicate by TLDA in the four conditions described above.
Estrogen-receptor (ER) α and β expressions were analysed
in the three human cell lines. In MCF-7 cell line, we
observed a decreased expression of ERα  and an over-
expression of ERβ after BRCA2 knockdown, as well as after
additional treatments of both genistein and daidzein.
MDA-MB-231 breast cancer cells showed a decreased
expression of ERα and ERβ genes in all conditions. The
fibrocystic MCF-10a cell line showed a down-regulation
of ERα expression after BRCA2-siRNA transfection, but no
significant modulations were observed under additional
isoflavone treatments. No significant modulations were
observed for ERβ  expression which is not usually
expressed (Figure 2).
Expression of thyroid-related receptors such as Thyroid
hormone receptor α-1-like, REV-ERBA-α-related receptor,
THR α-1, THR β-2, V-ERB-A avian erythroblastic leukemia
viral oncogene homolog-like 2 was also modulated after
BRCA2-siRNA treatment and the additional phytoestro-
gen treatments (Figure 3).
We also observed modulation in retinoic acid-related
receptors such as RARα, RARβ, RARγ, RXRα, and RXRβ
after the different treatments (Figure 4).
Liver X-related receptors (LXR) α and β expressions were
not affected by BRCA2-siRNA transfection, except in
MDA-MB-231. The hepatocyte nuclear factor (HNF) 4-γ
expression was decreased after the both 72 hours treat-
ments (Figure 5).
Peroxisome proliferator-activated receptor (PPARs) α, δ,
and γ expressions were also found modulated after the dif-
ferent treatments (Figure 6).
Hormone receptors as glucocorticoid, aldosterone,
growth factor and vitamin D receptors were studied and
showed modulations in their expressions after siRNA-
BRCA2  transfection and both genistein and daidzein
exposures (Figure 7).
Discussion
Epidemiological evidence suggests that consumption of
soy products is inversely correlated with the incidence of
certain types of cancers, including breast cancer. Genistein
and daidzein, the main soy-associated isoflavones, are
considered to be the most important components in soy
and have been largely studied in the last years. The cellular
and molecular mechanisms involved in these compound
actions, however, are not fully understood. Isoflavones
are structurally similar to endogenous estrogens of
humans and have both estrogenic and antiestrogenic
activities. Nuclear receptors are transcriptional factors that
play important roles in gene expression regulation and
physiological activities. Among these, receptors are sexual
hormone receptors, including estrogen receptors (ER)
which are critical in breast cancer. This is especially true
since most of breast cancers are considered to be estrogen-
dependent. Modulation of nuclear receptors seemed to be
an important and possible mechanism through which iso-
flavone such as genistein and daidzein could act on phys-
iological functions.
There is increasing evidence that the silencing of BRCA2
gene might be important in the pathogenesis of a signifi-
cant proportion of sporadic breast cancers where this gene
expression is often modulated [15]. To study this, we used
RNA interference in breast human cells (MCF-7, MCF-
10a, and MDA-MB-231) to down-regulate BRCA2  and
determine its contribution to nuclear receptor expression
at the transcriptional level. Genistein and daidzein 72
hours treatments were added to this transitory loss of
function and the expression pattern of 64 nuclear receptor
genes were investigated using the TaqMan Low-Density
Array (TLDA) technique.
Two subtypes of ER (α and β) were identified and showed
distinct tissue-specific distribution patterns. Isoflavones
can bind to both ER subtypes due to their structural simi-
larity to human endogenous estrogens. The ratio of ERα to
ERβ is a prognostic marker in breast tumors, in that ERβ
expression is indicative of more benign tumors, whereas
ERα indicates malignant, aggressive tumors [16,17]. The
three different cell lines used in this study exhibited differ-
ent ER status: MCF-7 (ERα+/ERβ+), MDA-MB-231 (ERα-/
ERβ+), and MCF-10a (ERα-/ERβ-). Under the BRCA2 loss
of condition function, we observed in MCF-7, a decreased
expression of ERα and an increased expression of ERβ.
Both genistein and daidzein treatments showed the same
effects in this cell line. In MDA-MB-231 cell line under
siRNA-BRCA2  and either siRNA-BRCA2  + genistein or
daidzein, we observed a down-regulation of ERα and β. In
MCF-10a, no expression modulation was observed for
ERβ, and under-expression of ERα was observed under
siRNA-BRCA2 condition. So, in the absence of BRCA2, the
decreased expression of BRCA2  seemed to affect ERα
mRNA expression in the three cell lines, whereas isofla-
vone treatments seemed to have no effect on ER expres-
sion.Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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Modulation in mRNA levels performed by TLDA for estrogen receptor genes (ERα and ERβ) with differential expression  between BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposure, compared to control cells corresponding to  value 0, in MCF-7, MCF-10a and MDA-MB-231 cell lines Figure 2
Modulation in mRNA levels performed by TLDA for estrogen receptor genes (ERα and ERβ) with differential 
expression between BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposure, compared to con-
trol cells corresponding to value 0, in MCF-7, MCF-10a and MDA-MB-231 cell lines. Values are means ± SD for n = 
3 assays. Statistical analysis were carried out by Student t-test (†, P < 0.01; *, P < 0.05).Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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Modulations in mRNA levels performed by TLDA for thyroid hormone receptor-related genes (Thyroid hormone receptor α-1- like, REV-ERBA-α-related receptor, THR α-1, THR β-2, V-ERB-A avian erythroblastic leukemia viral oncogene homolog-like 2) occurring  after BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposures, compared to control cells corresponding to value  0, in MCF-7, MCF-10a, and MDA-MB-231 cell lines Figure 3
Modulations in mRNA levels performed by TLDA for thyroid hormone receptor-related genes (Thyroid hor-
mone receptor α-1-like, REV-ERBA-α-related receptor, THR α-1, THR β-2, V-ERB-A avian erythroblastic leukemia 
viral oncogene homolog-like 2) occurring after BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone expo-
sures, compared to control cells corresponding to value 0, in MCF-7, MCF-10a, and MDA-MB-231 cell lines. Val-
ues are means ± SD for n = 3 assays. Statistical analysis were carried out by Student t-test (†, P < 0.01; *, P < 0.05).Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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Modulations in mRNA levels performed by TLDA for retinoic acid receptor-related genes (RARα, RARβ, RARγ, RXRα, and  RXRβ) occurring after BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposure when compared to control cells  corresponding to value 0, in MCF-7, MCF-10a, and MDA-MB-231 cell lines Figure 4
Modulations in mRNA levels performed by TLDA for retinoic acid receptor-related genes (RARα, RARβ, RARγ, 
RXRα, and RXRβ) occurring after BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposure when 
compared to control cells corresponding to value 0, in MCF-7, MCF-10a, and MDA-MB-231 cell lines. Values are 
means ± SD for n = 3 assays. Statistical analysis were carried out by Student t-test (†, P < 0.01; *, P < 0.05).Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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Modulation in mRNA levels performed by TLDA for liver receptor genes (LXRα, LXRβ and HNF4γ) with differential expression  between BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposure when compared to control cells corresponding  to value 0, in MCF-7, MCF-10a, and MDA-MB-231 cell lines Figure 5
Modulation in mRNA levels performed by TLDA for liver receptor genes (LXRα, LXRβ and HNF4γ) with differ-
ential expression between BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposure when com-
pared to control cells corresponding to value 0, in MCF-7, MCF-10a, and MDA-MB-231 cell lines. Values are 
means ± SD for n = 3 assays. Statistical analysis were carried out by Student t-test (†, P < 0.01; *, P < 0.05).Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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Modulations in mRNA levels performed by TLDA for peroxisome-related receptor genes (PPARα, PPARδ and PPARγ) with dif- ferential expression between BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone exposure when compared to control  cells corresponding to value 0, in MCF-7, MCF-10a, and MDA-MB-231 cell lines Figure 6
Modulations in mRNA levels performed by TLDA for peroxisome-related receptor genes (PPARα, PPARδ and 
PPARγ) with differential expression between BRCA2-siRNA treatment and BRCA2-siRNA with isoflavone expo-
sure when compared to control cells corresponding to value 0, in MCF-7, MCF-10a, and MDA-MB-231 cell 
lines. Values are means ± SD for n = 3 assays. Statistical analysis were carried out by Student t-test (†, P < 0.01; *, P < 0.05).Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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The regulation of cell growth and differentiation of nor-
mal and malignant cells by retinoids is mediated by the
retinoic acid receptors (RARs) and the retinoid × receptors
(R×Rs). These are members of the steroid hormone recep-
tor superfamily of transcription factors [18]. Most of
known isotypes of RARs and RXRs are expressed in breast
cells [19]. Yang & al, 1999 have shown that RARα expres-
sion is lower in normal breast cells and ER-negative breast
cancer cells (MDA MB 231 and MDA MB 435), compared
to ER-positive breast cancer cells (MCF7 and T47D) [20].
In our study, BRCA2  knockdown is associated with a
decreased expression of RARα in MCF-7 and MDA-MB-
231. After genistein and daidzein 72-h exposures, we
observed a restored expression of RARα in MCF-7, but this
was not the case in MDA-MB-231 cells. This observation
may be due to the different ER status exhibited by these
two cell lines.
Moreover, loss of RARβ has been observed in solid tumor
cells, including breast cancer [21]. This finding suggests
that the specific loss of RARβ expression may be an impor-
tant event during breast tumorigenesis. This hypothesis is
supported by the observation that introduction of RARβ
gene into breast cancer cell lines restored RA responsive-
ness to growth inhibition and induction of apoptosis
[22]. Other reports have shown that RARβ  RNA is
expressed at low levels in normal and immortal breast
cells, but it is absent in ER-positive breast cancer cells [23].
In our study, we observed the absence of RARβ described
above in MCF-7 ER-positive cells. In MCF-10a, BRCA2
knockdown over-expressed RARβ when isoflavone treat-
ments decreased its expression. In MDA-MB-231, we
observed a general decreased expression of RARβ under
the different treatments.
It has been reported that RARγ is expressed at similar low
levels in normal mammary epithelial cells, immortal
breast cells, and breast cancer [21]. In MCF-7 and MCF-
10a, we observed an under-expression of RARγ after both Figure 7
Modulations in mRNA levels performed by TLDA for hor- mone receptor genes (Photoreceptor-specific nuclear receptor,  Glucocorticoid receptor, Aldosterone receptor, Growth factor  inducible nuclear protein N10 and Vitamin D receptor) with dif- ferential expression between BRCA2-siRNA treatment and  BRCA2-siRNA with isoflavone exposure when compared to  control cells corresponding to value 0, in MCF-7, MCF-10a,  and MDA-MB-231 cell lines Figure 7
Modulations in mRNA levels performed by TLDA for 
hormone receptor genes (Photoreceptor-specific 
nuclear receptor, Glucocorticoid receptor, Aldosterone 
receptor, Growth factor inducible nuclear protein N10 
and Vitamin D receptor) with differential expression 
between BRCA2-siRNA treatment and BRCA2-siRNA 
with isoflavone exposure when compared to control 
cells corresponding to value 0, in MCF-7, MCF-10a, 
and MDA-MB-231 cell lines. Values are means ± SD for n 
= 3 assays. Statistical analysis were carried out by Student t-
test (†, P < 0.01; *, P < 0.05).Journal of Molecular Signaling 2009, 4:3 http://www.jmolecularsignaling.com/content/4/1/3
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BRCA2 knockdown and either genistein or daidzein treat-
ments.
Thyroid hormone receptors (THRs) function as nuclear
transcription factors to mediate thyroid hormone actions.
They are key regulators of many genes involved in choles-
terol and lipid metabolism. They also play important
roles in controlling growth, differentiation, development,
and carcinogenesis. THR are present in both breast tissue
and in breast tumor tissue, although the involvement of
these receptors in breast cancer is poorly understood, and
their combined effects with estrogens are not well studied
[24]. In a recent study, it have been suggested that thyroid
hormones and their receptors play a role in breast cancer
development and progression in promoting MCF-7 and
T47-D cell proliferation, and increasing the effect of 17β-
estradiol on cell proliferation [25]. In our study, different
profiles were observed between the different cell lines and
after the different treatments. Thyroid hormone receptor α-1-
like, REV-ERBA-α-related receptor and THR α-1 were over-
expressed in MCF-7 while they were under-expressed in
MDA-MB-231 and MCF-10a. Furthermore, no modula-
tion of phytoestrogen treatments was observed on BRCA2
knockdown effects.
The peroxisome proliferator activated receptors (PPARs)
belong to the nuclear hormone recptor family and play an
important regulatory role in lipid metabolism and adipo-
genesis [26]. Three PPAR genes have been identified in
mammalian species: PPARα, PPARβ/δ, and PPARγ [27].
Results of in vitro studies demonstrate that the soy isofla-
vones, particularly genistein and daidzein, were able to
activate both PPARα- and PPARγ-mediated gene expres-
sions [28]. Furthermore, genistein has been identified as a
ligand of the PPARγ receptor [29]. On recent studies, acti-
vation of PPARs has been identified as an approach to
induce differentiation and inhibit proliferation of cancer
lines. In ERα-cell lines MDA-MB-231 and MCF-10a, we
observed an under-expression of PPARα  and  PPARβ/δ
after BRCA2 knockdown. It is interesting to note that the
addition of genistein or daidzein treatment restored
PPARα and PPARβ/δ expressions in MDA-MB-231. Daid-
zein treatment restored their expression in MCF-10a cells
whereas genistein did not. In MCF-7, we observed a global
over-expression of PPARα and PPARβ/δ  and an under-
expression of PPARγ as observed in MCF-10a. In MDA-
MB-231, PPARγ were slightly over-expressed after BRCA2
knockdown. This increased after genistein or daidzein
treatments. These observations suggested that isoflavone
may modulate PPARs expression via ER-independent
mechanisms.
1α,25-Dihydroxyvitamin D3, the biologically active form
of vitamin D that interacts with the vitamin D receptor
(VDR), is a coordinate regulator of proliferation, differen-
tiation, and survival of breast cancer cells [30]. On the
basis of these findings, there has been considerable inter-
est in the therapeutic use of VDR agonists in the treatment
of breast cancer. Furthermore, studies with mice lacking
VDRs have established that vitamin D participates in neg-
ative growth control of the normal mammary gland and
that the disruption of VDR signaling is associated with
accelerated mammary tumor development [31]. In MCF-
7 and MCF-10a cells, we observed an over-expression of
VDR after BRCA2 knockdown and genistein and daidzein
treatments. In MDA-MB-231, we observed a decreased
expression of VDR after BRCA2 knockdown which was
reversed after isoflavone treatments.
In conclusion, generating the transitory knockdown of
BRCA2 oncosuppressor, we observed in three cell lines
different modulations in several nuclear receptor genes
like ER, RAR and RXR, as well as PPARs, and VDR. Addi-
tional treatments of genistein and daidzein, the main soy
isoflavones, showed the similar or the opposite nuclear
receptor gene modulation profiles that we observed under
BRCA2 knockdown in a cell line independent-manner.
These results suggested that many of the modulations
observed may implicate, either directly or indirectly, the
oncosuppressor  BRCA2  and an ER-independent cross-
modulatory action of genistein and daidzein for several
different receptors.
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